SEARCH

SEARCH BY CITATION

References

  • 1
    Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 1979;16:3240.
  • 2
    Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 1999;13:163174.
  • 3
    Bateman KE, Catton PA, Pennock PW, et al. 0–7-21 Radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 1994;8:267272.
  • 4
    Wallace J., Matthiesen DT, Patnaik AK. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg 1992;21:337341.
  • 5
    Blackwood L., Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996;209:98102.
  • 6
    Theon AP, Rodriguez C., Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 1997;210:778784.
  • 7
    Salisbury SK, Lantz GC. Long-term results of partial mandibu-lectomy for treatment of oral tumors in 30 dogs. J Am Anim Hosp Assoc 1988;24:285294.
  • 8
    Schwarz PD, Withrow SJ, Curtis CR, et al. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc 1991;27:601609.
  • 9
    MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:42494258.
  • 10
    MacEwen EG, Patnaik AK, Harvey HJ, et al. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 1986;4:397402.
  • 11
    Thompson JM, Dhoodhat YA, Bleehen NM, et al. Microwave hyperthermia in the treatment of spontaneous canine tumours: An analysis of treatment parameters and tumour response. Int J Hyperthermia 1988;4:383399.
  • 12
    Theon AP, Madewell BR, Moore AS, et al. Localized thermo-cisplatin therapy: A pilot study in spontaneous canine and feline tumours. Int J Hyperthermia 1991;7:881892.
  • 13
    Hall EJ. Chemotherapeutic agents from the perspective of the radiation biologist. In: Radiobiology for the Radiologist. Philadelphia , PA : JB Lippincott; 1994: 224, 302–304.
  • 14
    Steel RGD, Torrie JH. Contigency tables. In: SteelRGD, TorrieJH, ed. Principles and Procedures of Statistics. New York , NY : McGraw-Hill; 1980: 495520.
  • 15
    Theon AP, Madewell BR, Ryu J., Castro J. Concurrent irradiation and intratumoral chemotherapy with cisplatin: A pilot study in dogs with spontaneous tumors. Int J Radiat Oncol Biol Phys 1994;29:10271034.
  • 16
    Hahn KA, Rohrbach BW, Legendre AM, et al. Hematologic changes associated with weekly low-dose cisplatin administration in dogs. Vet Clin Pathol 1997;26:2931.
  • 17
    Ogilvie GK, Krawiec DR, Gelberg HB, et al. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 1988;49:10761078.
  • 18
    Shott S. Survival analysis. J Am Vet Med Assoc 1991;198:15131515.
  • 19
    Ogilvie GK, Moore AS. Tumors of the oral cavity. In: OgilvieGK, MooreAS, ed. Managing the Veterinary Cancer Patient. Trenton , NJ : Veterinary Learning Systems Co; 1995: 332336.
  • 20
    Thomas RC, Fox LE. Tumors of the skin and subcutis. In: MorrisonWB, ed. Cancer in Dogs and Cats, Medical and Surgical Management. Baltimore , MD : Williams and Wilkins; 1998: 499500.
  • 21
    Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog: A retrospective study of 361 cases. J Am Vet Med Assoc 1979; 175:567571.
  • 22
    Harvey HJ, MacEwen EG, Braun D., et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 1981;178:580582.
  • 23
    Overgaard J., Overgaard M., Hansen PV, et al. Some factors of importance in the radiation treatment of malignant melanoma. Ra-diother Oncol 1986;5:183192.
  • 24
    Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 1982; 8:11311134.
  • 25
    Ashby MA, Ago CT, Harmer CL. Hypofractionated radiotherapy for sarcomas. Int J Radiat Oncol Biol Phys 1986;12:1317.
  • 26
    Hornsey S. The relationship between total dose, number of fractions and fraction size in the response of malignant melanomas in patients. Br J Radiol 1978;51:905909.
  • 27
    Overgaard J. The role of radiotherapy in recurrent and meta-static malignant melanoma: A clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986;12:867872.
  • 28
    Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980;6:4144.
  • 29
    Guptill L., Knapp DW, Hahn K., et al. Retrospective study of cisplatin treatment for canine malignant melanoma. Veterinary Cancer Society 13th Annual Meeting, Columbus, OH, 1993.
  • 30
    Kraegel SA, Page RL. Advances in platinum compound chemotherapy. In: KirkRW, BonaguraJD, ed. Current Veterinary Therapy XII. Philadelphia , PA : WB Saunders; 1992: 395399.
  • 31
    Ruslander DM, Price GS, McEntee MC, et al. Intravenous melphalan: Phase II evaluation in dogs with malignant melanoma. Veterinary Cancer Society 13th Annual Meeting, Columbus, OH, 1993.
  • 32
    Weichselbaum RR, Chen G., Hallahan DE. Biological and physical basis of radiation oncology. In: HollandJF, FreiE., BastRC, KufeDW, MortonDL, WeichselbaumRR, ed. Cancer Medicine, 4th ed., vol 1. Baltimore , MD : Williams and Wilkins; 1997: 714.
  • 33
    Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). J Am Vet Med Assoc 2001;218:14441448.